

Preliminary Program (as of 12/19/2014)

ATA Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer

12:00 p.m. – 12:30 p.m. Lunch available to all registered attendees

12:30 p.m. – 12:40 p.m. **Background (Andrew J. Bauer)**

- Pediatric Task Force Composition and Guidelines Process
- Pediatric Thyroid Nodules and Cancer---Why are Separate Guidelines Needed?

12:40 p.m. – 12:55 p.m. Pediatric Thyroid Nodules (Salvatore Benvenga)

- Incidence and Risk of Cancer
- Evaluation/Treatment of Pediatric Thyroid Nodules

12:55 p.m. – 1:10 p.m. **Pre-operative Staging and Surgery (Geoffrey B. Thompson)**

- Pre-Operative Staging
- Optimal Surgical Approach—Which Surgeon and What Procedure?

1:10 p.m. – 1:25 p.m. Risk Stratification and Post-operative Staging (Andrew J. Bauer)

- ATA Pediatric Thyroid Cancer Risk Stratification
- Post-Operative Staging Based upon Risk Stratification

1:25 p.m. – 1:40 p.m. The Role of RAI in Pediatric Thyroid Cancer (Markus Luster)

- Indications for RAI in Pediatric Thyroid Cancer
- RAI Dose Selection

1:40 p.m. – 1:55 p.m. TSH Suppression and Surveillance (Catherine A. Dinauer)

- Role of TSH Suppression and TSH Goals
- Use of US, RAI Scans, and Thyroglobulin Levels in the Long-Term Follow Up of Pediatric Thyroid Cancer
- Appropriate Evaluation of the Patient with Known or Suspected Residual Disease

1:55 p.m. – 2:10 p.m. Management of Children with Distant Metastases (Steven G. Waguespack)

 Role of RAI and Other Systemic Therapies in the Management of Pulmonary Metastasis

2:10 p.m. – 2:40 p.m. Panel Discussion with Questions from the Audience (all speakers)

2:40 p.m. – 3:00 p.m. **Break**

ATA Management Guidelines for Medullary Thyroid Carcinoma

3:00 p.m. – 3:15 p.m.	 Background (Samuel A. Wells, Jr.) Etiology of Sporadic and Hereditary MTC Clinical Characteristics and Relationship between Genotype and Phenotype of Sporadic and Hereditary MTC
3:15 p.m. – 3:30 p.m.	 Initial Evaluation of Patients with a Thyroid Nodule and Suspected MTC (Robert F. Gagel) Direct DNA Analysis to Detect RET Germline Mutations in Patients with Apparent Sporadic MTC Secretory Products of MTC
3:30 p.m. – 3:45 p.m.	Ethical Considerations for Genetic Screening (M. Sara Rosenthal)
3:45 p.m. – 4:00 p.m.	 Management of Patients with Clinically Evident MTC (Douglas B. Evans) Management of Patients with MTC confined to the Thyroid Gland Management of Patients with Advanced Local Disease Management of Patients Who Have Had an Inadequate Initial Operation
4:00 p.m. – 4:15 p.m.	 Management of Children with Hereditary MTC (Steven G. Waguespack) Prophylactic Thyroidectomy in Children with MEN2A or MEN2B
4:15 p.m. – 4:30 p.m.	Management of Pheochromocyomas and Parathyroid Tumors in Patients with Hereditary MTC (Douglas B. Evans)
4:30 p.m. – 4:45 p.m.	 Treatment of Patients with Metastatic MTC (Bruce G. Robinson) Management of patients with distant metastases Management of patients with hormonally active metastases

Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer Faculty

Panel Discussion with Questions and Answers from the Audience (all speakers)

- Andrew J. Bauer, M.D., Children's Hospital of Philadelphia, Philadelphia, Pennsylvania
- Salvatore Benvenga, MD, Policlinico Universitario di Messina, Italy

4:45 p.m. – 5:15 p.m.

- Steven G. Waguespack, M.D., University of Texas M.D. Anderson Cancer Center, Houston, Texas
- Catherine A. Dinauer, M.D., Yale University School of Medicine, New Haven, Connecticut
- Markus Luster, M.D., University of Marburg and University Hospital Marburg, Marburg, Germany
- Geoffrey B. Thompson, M.D., Mayo Clinic, Rochester, Minnesota

<u>Guidelines for the Management of Medullary Thyroid Carcinoma Faculty</u>

- Douglas B. Evans, M.D., Medical College of Wisconsin, Milwaukee, Wisconsin
- Robert F. Gagel, M.D., The University of Texas M. D. Anderson Cancer Center, Houston, Texas
- Bruce G. Robinson, M.D., The University of Sydney, Sydney, Australia
- M. Sara Rosenthal, Ph.D., University of Kentucky, Lexington, Kentucky
- Steven G. Waguespack, M.D., University of Texas M.D. Anderson Cancer Center, Houston, Texas
- Samuel A. Wells, Jr., M.D., National Cancer Institute, National Institutes of Health, Bethesda, Maryland